Scientists, businessmen and simply interested in research and promotion
of
new bioengineering materials, we can offer you angiogenin that is the
result
of our last successful research project.
1. The independent private enterprise "Biok" was founded by
scientists and
businessmen for the purpose of realization and commercial application
of the
intellectual property of the founders. We would like to offer
you the
angiogenin substance and biotechnological method for its production.
2.Angiogenin is a member of angiogenic proteins-substances, which
stimulates
the growth of the blood vessels. Angiogenin is a basic single-chain
protein of
about 14 kD. It consists of 123 amino acids. In contrast to other
angiogenic
substances angiogenin has no direct mitogenic effect on
fibroblast and
endothelial cells, although it binds to endothelial cells of blood
vessels.
Angiogenin possesses strong angiogenic activity in biological
assays
( in choricallantoic membrane of developed chicken and on rabbit
corneal )
at dose as low as 1-5 ng.
Mechanisms of its actions and physiological roles are being
investigated.
Nevertheless it's clear now that thanks to its' remarkable effects
angiogenin
seems to be a good substance for development of efficient drug on
its base.
It can be used for healing of wounds, for treatment of the cerebral
thrombosis
and myocardial infarction and other pathological conditions which are
caused by
neovasoularization disturbances.
More over, on the base of the substance new diagnostic kits for
detection of
angiogenin presence in human tissue and biological fluids may be
constructed as
well as radioreceptor assay.
3. We have developed the original technology for production of
angiogenin.
Human recombinant angiogenin obtained is synthesized by original
recombinant
bacterial strain. It is of high biochemical and immunochemical
purity and
possesses high biological activity. Substance could be used for research
goals.
At present the preclinical trials of produced angiogenin is being
carried out.
4. Our firm has developed and produced a bioreactor of a new
type for
suspension cultivation of tissue cells and recombinant bacterial
strain.
The bioreactor embodies a new principle of stirring a cell suspension
without
a stirrer. The suspension is agitated by creating quasi-stationary
three-dimensional
motion similar to a otating vortex ring, generated by the aerating gas
flow.
5. The novelty of recombinant bacterial strain and bioreactor are
protected by
patents in Russia.
6. We would like to offer you :
- supply angiogenin as biomaterial for your laboratories and other
needs.
- sale of bioreactor with working volume 5 and 10 dm^3
- "Biok" is interested in partners for organization joint ventures
producing angiogenin substance.
- "Biok" is interested in partners for organization joint ventures
producing
bioreactors mentioned above.
We are ready to listen to your any idea upon that subject.
Sincerely yours,
Yuri Ramazanov, Director of "Biok"
Prof. Nikolai P. Mertvetsov, M. D. Ph. D, Deputy Director of
Novosibirsk Institute of Bioorganic
Chemistry, head of department of clinical research